Back to top
more

Lantheus (LNTH)

(Delayed Data from NSDQ)

$97.33 USD

97.33
648,582

+0.07 (0.07%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $97.39 +0.06 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Henry Schein's Merritt Buyout to Boost U.S. Veterinary Arm

by Zacks Equity Research

Henry Schein's (HSIC) acquisition of Merritt Veterinary supplies will brace its existing U.S. animal health business, particularly in the southeastern United States.

    LabCorp & Interpace Extend Deal, Boost Cancer Portfolio

    by Zacks Equity Research

    LabCorp's (LH) agreement to offer Interpace Diagnostics' molecular tests, ThyGenX and ThyraMIR gets renewed and extended for another two years.

      Veeva (VEEV) to Gain Through Subscription Revenue Focus

      by Zacks Equity Research

      Veeva's (VEEV) strong sales growth will continue to be aided by focus on subscription revenue, better pricing and product innovation. However, higher costs remain a concern.

        Zacks.com featured highlights Sanderson Farm, Heska Corp, Vanda Pharmaceuticals Lantheus and NVR

        by Zacks Equity Research

        Zacks.com featured highlights Sanderson Farm, Heska Corp, Vanda Pharmaceuticals Lantheus and NVR

          Hill-Rom (HRC) Stock Down With Dull Patient Support Systems

          by Zacks Equity Research

          Hill-Rom's (HRC) Patient Support Systems revenue decreases due to the adverse effect of the WatchChild and Architectural Products divestitures along with lower rental revenues.

            Here's Why Chemed (CHE) is a Suitable Growth Pick for Now

            by Zacks Equity Research

            Banking on favorable Net Margin and ROE, Chemed (CHE) stands out as one of the most suitable growth stocks.

              Express Scripts to Boost Oral Medication With Diabetes Study

              by Zacks Equity Research

              Express Scripts' (ESRX) new study will support oral diabetes medication and reduce related costs.

                IDEXX Laboratories (IDXX), Great Growth Pick: Here's Why

                by Zacks Equity Research

                Banking on a number of favorable metrics, IDEXX Laboratories (IDXX) stands out as one of the most suitable growth stock.

                  Tirthankar Chakraborty headshot

                  5 Efficient Stocks to Buy for a Healthy Portfolio

                  by Tirthankar Chakraborty

                  Companies with a favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with its price performance

                    Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength

                    by Zacks Equity Research

                    Luminex (LMNX) has a broad range of products that are built on advanced technology. Also, it has collaborative agreements with several companies, which should help expand the use of its products.

                      Chemed (CHE) on Growth Track With VITAS & Roto-Rooter Arms

                      by Zacks Equity Research

                      The raised outlook for both Roto-Rooter unit and the bottom line indicate Chemed's (CHE) estimate of improved operating results in the upcoming quarters.

                        Illumina Teams Up With Telegraph Hill to Form Verogen

                        by Zacks Equity Research

                        Illumina (ILMC) and Telegraph Hill Partners plan to set up Verogen to accelerate adoption of NGS in the global forensic genomics market.

                          Is Amedisys (AMED) a Great Value Stock for Your Portfolio?

                          by Zacks Equity Research

                          Banking on a number of favorable metrics, Amedisys (AMED) stands out as one of the most suitable value stock.

                            Here's Why Masimo (MASI) is a Suitable Value Pick for Now

                            by Zacks Equity Research

                            Masimo (MASI) seems to be a solid value pick with favorable P/E ratio and P/FCF ratio compared with its broader industry.

                              LabCorp to Add ChromaDex's Arm, Inorganic Expansion On Track

                              by Zacks Equity Research

                              LabCorp's (LH) decision to buy the analytical testing services arm of ChromaDex should fortify its Covance Food Solutions business.

                                Thermo Fisher's Patheon Buyout Gains Antitrust Clearance

                                by Zacks Equity Research

                                Thermo Fisher (TMO) gets antitrust clearance to move a step closer toward completion of Patheon acquisition.

                                  Medtronic's (MDT) CE Mark in Heart Lead Strengthens CVG Arm

                                  by Zacks Equity Research

                                  Medtronic's (MDT) CVG arm continues to be the highest revenue grossing segment. Thus, the company's CE Mark receipt for Attain Stability Quad MRI SureScan Active-Fixation heart lead buoys optimism.

                                    Ecolab Sales Solid Amid Escalating Delivered Product Costs

                                    by Zacks Equity Research

                                    Ecolab's (ECL) strong sales growth will continue to be aided by new business gains, better pricing and product innovation. However, higher delivered product costs remain a concern.

                                      Bruker Launches D8 VENTURE BIOTOOLS for Home Laboratory

                                      by Zacks Equity Research

                                      Bruker's (BRKR) D8 VENTURE BIOTOOLS for laboratory macromolecular crystallography has some latest features in terms of source, detector and sample handling technology.

                                        Omnicell (OMCL) Gains on Product Launches, Competition Rife

                                        by Zacks Equity Research

                                        Omnicell (OMCL) launches AcuDose software on XT hardware which allows Aesynt customers to fully benefit from XT. The company also launches XT Series Automated Supply Dispensing system.

                                          Here's Why Investors Should Buy Amedisys (AMED) Right Now

                                          by Zacks Equity Research

                                          Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.

                                            Align Technology's Invisalign Sales Strong Amid Margin Woes

                                            by Zacks Equity Research

                                            Align Technology's (ALGN) huge InvisAlign prospects in North America and international regions render optimism. However, escalating costs and expenses put pressure on the company's margins.

                                              LabCorp Partners OmniSeq to Grow in Immuno-Oncology Space

                                              by Zacks Equity Research

                                              LabCorp (LH) decides to distribute OmniSeq's molecular diagnostics assays in the United States and beyond to grow in immuno-oncology space.

                                                Cerner (CERN) Banks on RCM & PH Platforms, Competition Rife

                                                by Zacks Equity Research

                                                Cerner's (CERN) growth in order bookings would continue to boost growth prospects. However, steep competition in the HCIT space raise concern.

                                                  Quality Systems Professional Service a Drag, Competition Rife

                                                  by Zacks Equity Research

                                                  Quality Systems' (QSII) performance in the professional service business continues to be a drag in recent times. Also, macro headwinds continue to put pressure on performance.